Pediatric Gastroenterology Department, Federal University of Sao Paulo, Sao Paulo, Brazil.
Department of Health, Education and Society, Institute of Health and Society, Federal University of São Paulo - Baixada Santista Campus, Santos, Brazil.
Allergol Immunopathol (Madr). 2023 Mar 1;51(2):177-183. doi: 10.15586/aei.v51i2.768. eCollection 2023.
To compare the effectiveness of extensively hydrolyzed protein-based formula (EHF) or amino acid-based formula (AAF) in reversing the weight and height deficit in infants on a cow's milk protein elimination diet.
Infants from a retrospective cohort who were fed EHF (n = 17) or AAF (n = 16) for at least 2 months on a cow's milk protein elimination diet were included. The weight and height values recorded in the infants' medical records were obtained.
The mean age of the infants at the start of EHF and AAF were 5.8 ± 2.6 and 4.4 ± 2.5 months, respectively (P = 0.061). There was no difference between the groups in terms of the monthly weight gain (373.0 ± 212.2 and 453.1 ± 138.5 g, P = 0.223, respectively, for EHF and AAF), while the monthly increase in height was greater in the group fed with AAF (1.3 ± 0.5 and 1.8 ± 0.6, P = 0.030). A comparison between the difference in the initial z-score and in the oral challenge test of weight-for-age (+0.7 ± 1.2 and +1.3 ± 1.4, P = 0.262, respectively, for the EHF and AAF groups), height-for-age (+0.2 ± 1.1 and +1.2 ± 1.8, P = 0.090), and body mass index (BMI)-for-age (+0.7 ± 1.3 and +0.7 ± 1.5, P = 0.971) did not reveal a statistically significant difference between the groups. Correlation coefficients showed that the greater the initial nutritional deficit, the greater the positive variation between the beginning of each formula and the oral challenge test.
EHF and AAF provided similar increases in the weight-for-age, height-for-age, and BMI-for-age z-scores in both groups. The monthly increase in height was greater in infants who received AAF.
比较深度水解蛋白配方(EHF)或氨基酸配方(AAF)在逆转牛奶蛋白过敏婴儿接受饮食排除治疗后体重和身高不足方面的有效性。
回顾性队列研究纳入至少接受 2 个月 EHF(n=17)或 AAF(n=16)治疗的婴儿。从婴儿病历中获取体重和身高值。
EHF 和 AAF 开始时婴儿的平均年龄分别为 5.8±2.6 个月和 4.4±2.5 个月(P=0.061)。两组间每月体重增加量(EHF 和 AAF 分别为 373.0±212.2 和 453.1±138.5g,P=0.223)和每月身高增加量(EHF 和 AAF 分别为 1.3±0.5 和 1.8±0.6,P=0.030)均无差异。AAF 组体重-年龄 Z 评分初始差值和口服挑战试验差值(EHF 和 AAF 组分别为+0.7±1.2 和+1.3±1.4,P=0.262)、身高-年龄 Z 评分初始差值和口服挑战试验差值(EHF 和 AAF 组分别为+0.2±1.1 和+1.2±1.8,P=0.090)、体重指数(BMI)-年龄 Z 评分初始差值和口服挑战试验差值(EHF 和 AAF 组分别为+0.7±1.3 和+0.7±1.5,P=0.971)比较均无统计学差异。相关系数表明,初始营养不足越大,两种配方开始到口服挑战试验之间的正变化越大。接受 AAF 的婴儿身高增加更大。
EHF 和 AAF 均能使两组体重-年龄、身高-年龄和 BMI-年龄 Z 评分增加,接受 AAF 的婴儿身高每月增长幅度更大。